Axsome at Leerink Global Biopharma: Strategic Advances in 2025

On Wednesday, 12 March 2025, Axsome Therapeutics (NASDAQ: AXSM) shared its strategic vision at the Leerink Global Biopharma Conference 2025. The company highlighted recent FDA approvals, expanded commercial efforts, and forthcoming clinical milestones. While the outlook remains positive with new product launches and trial readouts, challenges such as competitive pressures and the need for strategic marketing were also discussed.

Key Takeaways

• FDA approved Simbravo for acute migraine treatment.
• Ovelity’s patent protection extended to 2039 with pediatric exclusivity.
• AXS-05 submission for Alzheimer’s agitation expected in Q3.
• Expanded sales force to 300 representatives for broader market reach.
• Upcoming trial readouts for ADHD and MDD anticipated this quarter.

Financial Results

• Axsome’s total net revenue for 2024 reached approximately $386 million.
• Ovelity, a key product, contributed $291.92 million to revenue.
• Gross-to-net ratio is expected to remain steady at around 50%.
• Ovelity coverage includes 78% of total lives, with full government channel coverage and 63% in the commercial channel.

Operational Updates

• The sales force was expanded by 40 representatives, totaling 300.
• The impact of this expansion on new and total prescriptions is expected within one to two quarters.
• A broader direct-to-consumer campaign is planned, emphasizing Ovelity’s rapid action and distinct tolerability.
• Simbravo, Axsome’s third product, will target headache centers with a dedicated sales team.

Future Outlook

• The company plans to initiate a Phase 2/3 trial for smoking cessation this year.
• NDA submission for AXS-12 in narcolepsy is expected later this year.
• AXS-14 for fibromyalgia is nearing potential FDA acceptance, with a launch anticipated next year.
• Axsome aims to partner internationally for Ovelity and other products to align with regional patient needs.

Q&A Highlights

• Ovelity utilization is increasing in earlier treatment lines, with 15% in first line and 35% in second line.
• Simbravo will focus on patients inadequately responding to existing migraine therapies.
• AXS-12 is expected to complement Sunosi in the narcolepsy market if approved.

Readers are encouraged to refer to the full transcript for a detailed account of Axsome Therapeutics’ strategic initiatives and financial performance.

Full transcript - Leerink Global Biopharma Conference 2025:

Mark, Host: Session. Thank you very much to Axsome Therapeutics for being here. We have Mark Jacobson, who’s the COO of the company. And Mark, I’m going to let you make a quick opening comment, and then we’ll jump right into it. So

Mark Jacobson, COO, Axsome Therapeutics: Sure. Well, thanks a lot, Mark, for having us. Really, really appreciate it. And it’s great to be at the conference. So 2025 is already just a great year for Axsome, and that’s on the heels of a great 2024, where we had total net revenue of about $386,000,000 and for Ovelity in particular, it was about $291,000,000 90 2 million dollars So just very pleased with execution on the commercial side of the business for really our second full year of commercial sales for Ovelity.

And already, as I mentioned, we started the year very strong. So approval of Simbravo for the acute treatment of migraine, that’s now our third product and the second product that Axsome has internally developed. So we’re very proud of that and we’re the work is underway to launch that in the coming months, and so we can talk about that. The other developments that have already occurred so far this year, the settlement of the patent litigation for Ovelity, and we have a final date now, and that takes us to March 2039 with pediatric exclusivity or September 2038 without it. So we feel very good about that and then what that means for the potential for ovellody and impacting patient lives and of course then the business impact to Axsome as a result.

And then the other, the other big development so far this year already, we recently announced the pre NDA meeting minutes with FDA for our program in Alzheimer’s disease agitation with AXS-five. And so we know what we need to do and we have alignment on the content and format of that submission. So it’s full steam ahead for a 3Q submission, and that will be via an sNDA. So already this year, a lot has happened and there’s much more to go. So I touched on some of those things, the launch of some Bravo and, sNDA submission for ovality and Alzheimer’s disease agitation.

And this quarter, we have, you know, we’ve guided for this quarter readouts for salriamfetol in the phase three focus trial in ADHD and the Phase III PARADIGM trial in MDD. So those are, you know, no change to guidance there. And then beyond that, it will be continued commercial execution and just execution on the ongoing programs on the clinical side of the house and also at least one other program that will launch clinical program that will launch, which is smoking cessation. So very pleased with the prior year and how this year started and what lies ahead of

Mark, Host: us for the rest of the year. A lot going on there. Yes. Okay. Let’s start with Avelity.

Sure. So what are kind of the key changes in strategy from a marketing perspective kind of going into this year? Great.

Mark Jacobson, COO, Axsome Therapeutics: So much is just staying the course and the plan, and we’re pleased with how launch is going. One, I would say, one update or expansion is simply an additional expansion to the sales representative team. So this quarter, we added about 40 additional reps to the team. So we’re now the Avelity field force is about 300 sales representatives. And those new team members are in the field, so they’ve gone through training and they are actively in the field now.

And we’d expect to start to see impact from, say, from NBRx and beyond, so flowing into TRx in one to two quarters. And that’s similar to what we saw last year when we expanded the field force. So we have that. And the other, the other, say, expansion of strategy and tactics would be our plans with respect to a broader or larger DTC effort, which we, are planning

Mark, Host: to do later this year. Going on television, streaming across the board.

Mark Jacobson, COO, Axsome Therapeutics: Exactly. So, I mean, I don’t know about across the board, but but, definitely in and what I mean by that is it it’s it’s not go you know you know the approach will be it will be TV linear TV and and other kind of other components online. But I didn’t mean, you know, nightly news, Super Bowl ads, things like that. So it will be kind of in our fashion of, of seeking high ROI and highly rational deployment

Mark, Host: of Targeted. Targeted. Very targeted. Yep. Yep.

Yep. What about the marketing message on the DTC? Is this going to be, you know, you’re going to focus on the new mechanism, you’re going to focus on the speed to act, like what’s the

Mark Jacobson, COO, Axsome Therapeutics: The, I mean, that’s all coming together right now, but what really resonates is just how patients do when they take their product, in particular that it works quickly, so that it’s fast, that the efficacy is durable, so that it lasts, and also that the tolerability profile is distinct from, you know, classic AEs that are associated with antidepressants. And that really resonates with patients and prescribers. So, you know, the focus will be on education around those elements of Avelity.

Mark, Host: And just remind us how the product is being used in the real world. Yes. So right now,

Mark Jacobson, COO, Axsome Therapeutics: kind of where things are as of the last quarter is 50% of utilization was in first or second line. And that split and obviously, the rest is goes third and beyond. And that split was about fifteen percent first line and thirty five percent second line. So we really like that in terms of specifically where we are at this point in launch, and we expect those trends to continue. That’s been growing slowly over time, earlier line use.

We expect that to continue, and we’re pleased with that. And, yeah, we’ll see how it goes. But I think that that speaks to and that ties to just how patients do and clinicians, HCPs, nurse practitioners, they see it and then that helps them think about other potential appropriate patients and moving it up to earlier line use. Any bumps along

Mark, Host: the road in the past year or two that you’ve had to kind of fix and that you can point out and say, okay, we’ve got this, know, if you heard this story, don’t worry about it, we fixed

Mark Jacobson, COO, Axsome Therapeutics: it kind of thing, anything? Or Oh, Nothing major. Nothing major. I you know, there are things that are just elbow grease and and I think it’s mostly honing in on, to your point about messaging and how potential prescribers and now patients are educated on the product. Yes.

Mark, Host: What about coverage? Update us on coverage and how you’re thinking about that.

Mark Jacobson, COO, Axsome Therapeutics: Yes. So coverage is about 78% of lives total. So that’s essentially everyone, 100% in the government channel and about 63% in the commercial channel. And so that’s been growing over time and our strategy has been to expand and evolve coverage in a steady and patient fashion while we drive demand and there’s additional trial and patients do well. And two, continue to add covered lives in the commercial channel.

So that strategy has been the strategy since launch, and it will continue. And we continue to expect additional lives in the commercial channel to be covered. And so stay tuned for updates.

Mark, Host: Yes. Just remember at the beginning, the strategy was let’s show the payers that we can actually this is a product that matters. Now that you’ve done that, the negotiating position has been more favorable. And are you looking to sign up the rest? Do you have one of the big PUMs?

I’m trying to remember.

Mark Jacobson, COO, Axsome Therapeutics: Yes, I think we shared that two of the GPOs. And so that was the last update we provided. And so, you know, stay tuned for updates to that situation. But it’s moving along. And I think that also ties to that it’s being used earlier in treatment.

Right? So initially, when whenever a new branded product comes to market, you have NDC blocks. So new products perplexingly are used in the latest line patients. And depending on how they do, they either kind of stay there or if prescribers see good responses, they’ll look for other appropriate potential patients and early in the treatment paradigm. That’s what we’re seeing.

So we’re seeing that volume and then payers see that. So that dynamic is still in place. And then of course, then that corresponds to the additional expansion for the sales team, deployment of a broader DTC effort.

Mark, Host: What percent right now are primary care doctors that are running here? The

Mark Jacobson, COO, Axsome Therapeutics: it’s a good question. I don’t have the exact percentage for you. The majority are still psychiatrists. But part of the recent expansion is the demand in the primary care setting to go wider or within primary care physicians. So we like that.

And then that also ties to already where we’re seeing utilization that makes sense, right? So first and second line MDD patients, right, they tend to be first seen. They tend to first see their primary care physician depending on where they are. Geographically, if they’re near urban centers or not, they’ll either stay in primary care or they may see a psychiatrist. But you know, the majority is are still, it’s still psychiatrists.

The majority of writers are still psychiatrists, but it’s growing in primary care.

Mark, Host: And last question is, gross to net. Just give us a sense of any major changes in gross to net this year versus last year.

Mark Jacobson, COO, Axsome Therapeutics: The I mean, we’ve said that, hey, you know, steady state, we expect to be in line with the class, which is like in the 50s, but ended, you know, ended at about 50%, ended the year at about 50%. And what you typically see in Q1 is you typically see that increase a little bit in the class, and we saw that last year for O’Vality specifically. So we’d expect Over the course of the year. Yes. A flattish versus

Mark, Host: last year full year.

Mark Jacobson, COO, Axsome Therapeutics: Yes. Generally in line. And what’s maybe some evolution in terms of, you know, towards steady state, just as additional covered lives come online, you may see some changes, but we expect to kind of be in the zone that we’ve been in recently.

Mark, Host: AD agitation, everyone’s excited about that potential indication. Just talk about what did the FDA kind of say? Where are we here? I think we and I would just say that there was always concerns from the investment community of, do you have enough positive data? Yes.

So how do you feel about that? Do you feel better today than you did three months ago?

Mark Jacobson, COO, Axsome Therapeutics: We felt very good three months ago or whatever that I guess it would be three months ago for when the data went out. When the trials, yeah, we felt very good. I mean, three positive studies, that’s, that’s, I think you would always look for a package like that. And the, I think the only reason you would say you’d feel better is you’ve you’ve got feedback, written feedback from from the FDA about, the plan for the submission and what will be in the submission from, you know, from a clinical efficacy safety package perspective. So both content and format of the submission.

So it’s always great before a submission, right, and now we have experience getting two products approved with different divisions at the agency. It’s very helpful to just have alignment and you let the agency know that the submission is coming and then just get their perspective on the overall package and that included, right, what the presentation is, is the full clinical package. So the four placebo controlled trials, right, three of which, which were positive and then the long term safety database.

Mark, Host: So we ran these extra studies for safety. Now we have the safety. You’ve checked the box on safety.

Mark Jacobson, COO, Axsome Therapeutics: Oh, we have alignment on the safety package

Mark, Host: as well. And I think the other investor concern was, is a withdrawal study an appropriate study for FDA? And now you have actually two positive withdrawal studies.

Mark Jacobson, COO, Axsome Therapeutics: So

Mark, Host: I think everybody is like much more confident because you have two. But it’s interesting, your view is even one would have been good enough.

Mark Jacobson, COO, Axsome Therapeutics: I mean, yes, the you know, don’t take our word for it. Just look at what’s required from a statutory perspective. It’s two adequate control trials and they can be the same trial paradigm or different, right? And actually, there are benefits to having two different trial designs.

Mark, Host: Yes. And so this is going to be an add on indication to the existing drugs. So you’ll market this product as Avelity. Avelity for AD agitation. And how do you look at it from the, there’s one product approved for today?

How do you view your marketing hook versus them?

Mark Jacobson, COO, Axsome Therapeutics: The so obviously, with only one product approved, there’s a dramatic need, patient need, and just for treatment options and approved treatment options with but then also a need is mechanistic differentiation, right. So what’s approved and is a distinct mechanism that there are other products that tend to be used off label, which are also just, you know, Avelity is distinct from those as well, right. It’s an NMDA receptor antagonist and based on the efficacy and tolerability data that we’ve generated to date and mechanistically it’s highly differentiated from what’s available.

Mark, Host: So We shouldn’t expect any added warnings or black box or, you know, nothing like that, which result in this still has.

Mark Jacobson, COO, Axsome Therapeutics: Yeah, I mean, it’s definitely distinct from a class perspective for the warnings that are that are on atypical antipsychotics.

Mark, Host: You know, exactly

Mark Jacobson, COO, Axsome Therapeutics: what the final label will look like, you know, you find that out, you know, 30, well, upon potential approval, right, and you have a sense when you, if you enter labeling negotiations. But right now, there’s nothing that we that’s on our mind or that is previewed that we would expect to be

Mark, Host: Smoking cessation is the next indication. Yes. Just talk about that just so I think everybody forgot about that, but

Mark Jacobson, COO, Axsome Therapeutics: It’s always been on our mind, but there’s been so much going on that, that, you know, we’ve been running air traffic control on all the programs and and choreographing, say, resource and deployment for, ASOS five. And the focus has always the additional development has been AD agitation. That’s been the primary focus. And now is the right time to start up the Phase two, three trial in smoking cessation. So that’s on track for this year.

Mark, Host: So this will be this is one pivotal and think you’d need two or

Mark Jacobson, COO, Axsome Therapeutics: Yes, like, that’s the expectation is two and that this would be the first of two. And so we’ll see. You’ll do

Mark, Host: one behind the other or you might even start a second?

Mark Jacobson, COO, Axsome Therapeutics: Yes. Probably that would be the case is sequentially.

Mark, Host: Just given the resources and the focus of it.

Mark Jacobson, COO, Axsome Therapeutics: Yeah. And also it’d be our first, it’d be our first study in the indication of that there was another study that wasn’t conducted by us. So Yep.

Mark, Host: So migraine, obviously, the CGRPs have made a lot of noise over the past five or six years. You’re getting ready to launch a new product in, in a few months. Talk about why people are going to use the product, what the hook is.

Mark Jacobson, COO, Axsome Therapeutics: Simbravo, we’re pretty excited about it and it ties to the data we generated and the mechanism of action, right. It’s multi mechanistic, so you’re looking to target the migraine cascade in

Mark, Host: multiple ways to

Mark Jacobson, COO, Axsome Therapeutics: abort the cascade, both of which are, abort the cascade, both of which are very rapid acting and that’s part of the technology. So it’s based on Axsome technology that we developed. So that’s the MOSAIC technology where you have a very rapid onset of action for two distinct mechanisms, but then for one of which you maintain a very long treatment effect. And that ties to, again, the technology where you have rapid absorption but an extended half life. And the data we’ve generated are in a number of migraine settings or patient profiles, in particular ones that have had inadequate response to prior oral acute therapy.

So just in general, prior you know, inadequate response to acute oral therapy and then in particular inadequate response to oral CGRP acute therapy. So, you know, and so the range of data showing, you know, positive treatment outcomes, pain relief, pain freedom, you know, durability, you know, twenty four hour pain relief, pain freedom, forty eight hour pain relief, pain freedom. So it’s it’s very it’s a very robust data set and I think that allows us to to now that clinicians have had a lot of time to, to understand patient profiles and appropriate patients for oral CGRPs and things like that, it’s it’s a nice time to be launching.

Mark, Host: So is this like a super triptan? Is that how you

Mark Jacobson, COO, Axsome Therapeutics: I know. I mean, it, I can see why someone would say that, but in our mind, it’s distinct. I mean, you obviously do have a triptan

Mark, Host: in a highly Well, the meloxicam has been turbocharged on top of a triptan, right? So you get that

Mark Jacobson, COO, Axsome Therapeutics: It’s not used. Meloxicam, it’s an NCE in migraine. And what that means is meloxicam, it’s never used acutely unless it’s a hospital setting with IV. But essentially, we have a, since you mentioned, essentially, we have an oral form of, you know, a highly potent NSAID with a very long half life that has IV like PK. So, yeah.

Mark, Host: And what’s the strategy for sales reps and advertising and then put another 100 people in the ground or something and

Mark Jacobson, COO, Axsome Therapeutics: Yes, we’ll say more Separate sales force. We’ll say more about that soon in terms of the numbers. But yes, there will be a distinct sales force. We’ll be what we have shared is we’ll be targeting headache centers. There are about 150 of those in The U.

S. And so that will be the primary area of focus in the early days of launch. And we think that makes a lot of sense. But to your point, sizing, we’ll share that soon, but it will be in our approach where we leverage our digital centric commercialization platform. And really what that is, is that allows us to meet clinicians where, you know, in the medium or venue that they prefer.

So that’s either a live detail or remote and the reps have the flexibility to engage across platforms or mediums. And so that basically they’re more efficient from a reach and frequency perspective.

Mark, Host: So let’s talk about narcolepsy. So I want to talk about just Sunosi, which a lot of people are not focused on, but it’s actually growing pretty well and just what you’re focused on there and anything different from this year versus last year in the narcolepsy. But then you have a second drug in narcolepsy. So kind of talk about it as, you know, as one. And then when you have both of them, what’s the strategy?

The

Mark Jacobson, COO, Axsome Therapeutics: status quo with respect to the current strategy from a commercialization and perspective for the on brand or the approved indications. And right, we have a sales team in place that it’s, you know, Sanozysleep. And so NOSI, it’s important to note, it’s approved for narcolepsy, but just for excessive daytime sleepiness. So excessive daytime sleepiness in narcolepsy and in patients with obstructive sleep apnea. AXS 12, the way we’ve developed that in the clinical trials that we conducted, which were positive, was looking at cataplexy and narcolepsy.

So, we looked at excessive daytime sleepiness as well and positive separation there too. But the field force, so next steps with respect to AXS twelve, just very quickly, plan to have a pre NDA meeting with the FDA and then to submit an NDA later this year. And so if that product were approved, then you can see synergy but not cannibalization. One place into the NT1 kind

Mark, Host: of a one place into everything else.

Mark Jacobson, COO, Axsome Therapeutics: That’s kind of how you think about it. That is how they cohabitate. That’s the wrong word. But Do

Mark, Host: you think you will need to increase the size of the Synosi Salesforce with that product too?

Mark Jacobson, COO, Axsome Therapeutics: Not necessarily. I mean, the one reason we really like AXS 12 is, aside from the product profile, is the commercial infrastructure and it’s already in place. So to add that to the bag is You need

Mark, Host: to get good leverage.

Mark Jacobson, COO, Axsome Therapeutics: Yes, exactly.

Mark, Host: Yes. Good. And so that product is, it’s going to be filed sometime This

Mark Jacobson, COO, Axsome Therapeutics: year, yes, this year. We haven’t All the boxes

Mark, Host: have been checked with respect to data that you need.

Mark Jacobson, COO, Axsome Therapeutics: Data is, the clinical work is done. So, yeah.

Mark, Host: So we have two studies coming on Sunosi. One is in ADHD, as you mentioned, one is MDD. So let’s just talk about the scenarios. ADD, this is in adults. Let’s say this study is positive.

What do we do next?

Mark Jacobson, COO, Axsome Therapeutics: If the study is positive, then the next thing is we need to run a study in pediatric adolescent patients. And that’s required by, by the FDA as part of an initial submission, an adult, while a pediatric trial is required. So that’s the next step.

Mark, Host: Right. So then you run that study and then you would get theoretically, if they both work, a full ADHD label basically. Yep. Kids and adults.

Mark Jacobson, COO, Axsome Therapeutics: Yes, that’s correct.

Mark, Host: That’s correct. And then an MDD, talk about that and that’s probably a little more nuanced, I suppose.

Mark Jacobson, COO, Axsome Therapeutics: That’s more nuanced. It’s in a way it’s, you know, it’s more speculative. The it’s based on KOL feedback and insights and how patients do and just patients that have are treated for excessive daytime sleepiness. Of course, they have improvements in sleepiness, but feedback from KOLs is just that there are global changes. So we wanted to explore that.

And in particular, with MDD, we’re interested in, about half of patients with MDD have excessive daytime sleepiness. So we’re interested in looking at if patients with and without excess daytime sleepiness. So that will be

Mark, Host: So is the study it has both patients in it? Correct.

Mark Jacobson, COO, Axsome Therapeutics: Yes. So it’s broadly MDD patients.

Mark, Host: We get data in in both. I mean you sub

Mark Jacobson, COO, Axsome Therapeutics: We we share yeah, we share that that is something that that we’ll be looking at with the study.

Mark, Host: So it’s possible that the total study is not STAT SIG, but one of the subpopulations is STAT SIG, which is the key one you’re looking at, and then we just go after that. Is that is that kind of what you’re saying?

Mark Jacobson, COO, Axsome Therapeutics: Yeah, I mean, we’ll we’ll we’ll know very soon how, what the data show. But I think if we see a signal, then we’d be excited about that. And then that would determine if we need, how many other studies we would need

Mark, Host: to run. Another drug that probably doesn’t get a lot of discussion is fibromyalgia. Talk about the timing of that product and how you see that playing out.

Mark Jacobson, COO, Axsome Therapeutics: That’s AXS12 for good grief that is AXS14. And so and what we shared there for fibromyalgia, the clinical data are very interesting. So obviously, impact on pain, that’s important. But if you look at the need and it’s, you know, it’s about seventeen million patients, so there are there are a lot of individuals living with fibromyalgia and pain is, of course, the primary. But the data we have with ASOS fourteen is that there’s also a dramatic impact on fatigue and which is really a key symptom or burden of the disease for individuals with fibromyalgia and there’s positive impact there.

So the product profile is very interesting and the what we shared is that that NDA submission, the last update, what we provided at the when we reported year end results was it was in publication phase of the submission. So the next potential update from us is potential FDA acceptance of the filing and then

Mark, Host: standardization. And there’s the audience there. I mean, that potentially is a filing in this year and a launch next year, right?

Mark Jacobson, COO, Axsome Therapeutics: Correct. And

Mark, Host: the Who’s the audience? What

Mark Jacobson, COO, Axsome Therapeutics: doing? The commercial team is doing that analysis right now, and there are a number of ways to there are a number of potential relevant prescribers, and we’ll comment on that soon. There has not been active promotion for some time, so there will be elbow grease with respect to that. But the targeting process is or the analysis, you know, sales ops analysis that’s underway right now.

Mark, Host: It will be targeted this is not a let’s go to the primary care physicians who are more of a targeted approach?

Mark Jacobson, COO, Axsome Therapeutics: The I mean, I’m sure it’s going to be targeted because that’s the way we do things. But there definitely are these patients with fibromyalgia, they see primary care first, right. And then depending on their clinician, they may be referred to a pain management specialist or a rheumatologist. So it can depend. And I think a lot of that may just correspond to the fact that there are not a lot of treatment options.

So the treatment paradigm has it will be beneficial to for prescribers and patients if there’s actually something new. And then there’s active promotion and education around, you know, potential treatment paradigms.

Mark, Host: All these products we’ve talked about are all in The United States as far as the opportunity. What’s the goals for OUS?

Mark Jacobson, COO, Axsome Therapeutics: The goals for OUS are to partner outside The U. S. And so that work is underway, of course, for Sinozy. We did that very quickly because there was a very direct and clear path to doing so. And for others, there are direct Ovelity is the key one, right?

Ovelity, so Ovelity now, there are multiple pathways, so to speak, in terms of clinical packages that have been completed, a de agitation, major depressive disorder, we haven’t commented on specific regulatory body approaches, but the business development plan outside The U.

Mark, Host: S. Is to partner. And was and maybe I’m just asking this, but is the reason that you haven’t partnered it yet is because you’re waiting for the other indications such that the partner can launch with everything all the indications at the same time from a timing perspective for IT?

Mark Jacobson, COO, Axsome Therapeutics: Ultimately, what happens with what’s launched when, that’ll depend. But with respect to specifics on business development, we don’t comment on them. But your observation that now we have multiple data sets that provides flexibility and allowing, say, calibration for patient needs in certain geographies, that we’re pleased with that. Good.

Mark, Host: Okay. So just to finish up, the next thing is the ADHD data and the MDD data, which are both going to occur basically in the next three weeks, right?

Mark Jacobson, COO, Axsome Therapeutics: Yes, before, you know, when it’s Q1. Yes, yes.

Mark, Host: Okay. All right.

Mark Jacobson, COO, Axsome Therapeutics: Thank you. You’re our last stop.

Mark, Host: All right. Thank you. Appreciate it. Thanks a lot. All right, man.

Thank you. Yes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.